BioCryst Pharmaceuticals Ownership | Who Owns BioCryst Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

BioCryst Pharmaceuticals Ownership Summary


BioCryst Pharmaceuticals is owned by 16.35% institutional investors, 1.32% insiders, and 82.32% retail investors. Vanguard group is the largest institutional shareholder, holding 10.60% of BCRX shares. BioPharma Credit Ord is the top mutual fund, with 8.23% of its assets in BioCryst Pharmaceuticals shares.

BCRX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockBioCryst Pharmaceuticals16.35%1.32%82.32%
SectorHealthcare Stocks 232.86%10.65%-143.51%
IndustryBiotech Stocks 382.13%10.41%-292.54%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Vanguard group22.27M10.60%$173.73M
Blackrock funding, inc. /de21.14M10.06%$164.87M
Blackrock19.96M9.68%$123.33M
Deerfield management company, l.p. (series c)12.17M5.82%$92.36M
State street9.81M4.69%$74.44M
Kynam capital management, lp9.39M4.49%$71.27M
Alkeon capital management5.46M2.61%$41.47M
Ubs group5.26M2.50%$41.06M
Arrowstreet capital, limited partnership5.23M2.50%$39.67M
Geode capital management5.05M2.40%$39.43M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Rp management3.85M12.84%$29.23M
Kynam capital management, lp9.39M5.31%$71.27M
Deerfield management company, l.p. (series c)12.17M1.41%$92.36M
Doliver advisors, lp374.33K0.81%$3.56M
Parkman healthcare partners1.01M0.80%$7.69M
Rice hall james & associates1.88M0.78%$14.27M
Rock springs capital management lp2.68M0.77%$20.14M
Eversept partners, lp1.37M0.72%$10.43M
Qtr family wealth157.06K0.63%$1.52M
Rfg advisory2.87M0.50%$27.33M

Top Buyers

HolderShares% AssetsChange
Deerfield management company, l.p. (series c)12.17M1.41%7.48M
Rfg advisory2.87M0.50%2.87M
Hood river capital management3.62M0.32%2.38M
Blackrock19.96M0.00%1.52M
Nantahala capital management1.36M0.35%1.36M

Top Sellers

HolderShares% AssetsChange
Morgan stanley1.75M0.00%-3.46M
Braidwell lp---3.38M
Avoro capital advisors1.25M0.12%-3.25M
Walleye capital227.06K0.01%-2.07M
Voloridge investment management957.02K0.02%-1.52M

New Positions

HolderShares% AssetsChangeValue
Rfg advisory2.87M0.50%2.87M$27.33M
Nantahala capital management1.36M0.35%1.36M$10.58M
Cubist systematic strategies1.25M0.05%1.25M$9.46M
Dimensional fund advisors lp1.23M0.00%1.23M$9.59M
Abrdn913.59K0.01%913.59K$7.13M

Sold Out

HolderChange
Tfo-tdc-3.00
Financial gravity asset management-8.00
Newedge advisors-11.00
Dinuzzo private wealth-13.00
Newbridge financial services group-15.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 202579-73.04%34,367,278-82.30%160.19%37-72.79%25-75.49%
Sep 30, 2025101-65.88%38,849,402-78.37%180.25%42-73.58%35-57.83%
Jun 30, 20253049.35%196,946,75415.72%941.42%1615.92%8630.30%
Mar 31, 20252772.59%174,118,1753.86%831.27%15029.31%66-25.00%
Dec 31, 2024265-1.49%167,630,080-2.81%811.17%114-14.29%8717.57%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
BioPharma Credit Ord17.22M8.23%17.22M
Vanguard Total Stock Mkt Idx Inv8.02M3.20%717.29K
Vanguard US Total Market Shares ETF6.57M3.14%-18.55K
State Street® SPDR® S&P® Biotech ETF6.66M2.65%100.17K
iShares Russell 2000 ETF5.51M2.20%-44.98K
SPDR® S&P Biotech ETF3.67M1.75%8.19K
Vanguard Small Cap Index2.89M1.15%262.87K
ACAP Strategic A2.70M1.08%-121.24K
Vanguard Institutional Extnd Mkt Idx Tr2.69M1.07%100.94K
Vanguard Strategic Equity Inv2.57M1.03%634.66K

Recent Insider Transactions


DateNameRoleActivityValue
Mar 20, 2026HEGGIE THERESA-Sell$504.82K
Mar 16, 2026Barnes Alane P Chief Legal OfficerSell$1.37M
Dec 22, 2025Barnes Alane P Chief Legal OfficerSell$166.56K
Dec 15, 2025Barnes Alane P Chief Legal OfficerSell$162.26K
Dec 01, 2025Barnes Alane P Chief Legal OfficerSell$646.51K

Insider Transactions Trends


DateBuySell
2026 Q4--
2026 Q1--
2025 Q4-6
2025 Q3-1
2025 Q2--

BCRX Ownership FAQ


Who Owns BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals shareholders are primarily institutional investors at 16.35%, followed by 1.32% insiders and 82.33% retail investors. The average institutional ownership in BioCryst Pharmaceuticals's industry, Biotech Stocks , is 382.13%, which BioCryst Pharmaceuticals falls below.

Who owns the most shares of BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals’s largest shareholders are Vanguard group (22.27M shares, 10.60%), Blackrock funding, inc. /de (21.14M shares, 10.06%), and Blackrock (19.96M shares, 9.68%). Together, they hold 30.34% of BioCryst Pharmaceuticals’s total shares outstanding.

Does Blackrock own BioCryst Pharmaceuticals?

Yes, BlackRock owns 9.68% of BioCryst Pharmaceuticals, totaling 19.96M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 123.33M$. In the last quarter, BlackRock increased its holdings by 1.52M shares, a 8.22% change.

Who is BioCryst Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Rp management is BioCryst Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 12.84% of its assets in 3.85M BioCryst Pharmaceuticals shares, valued at 29.23M$.

Who is the top mutual fund holder of BioCryst Pharmaceuticals shares?

BioPharma Credit Ord is the top mutual fund holder of BioCryst Pharmaceuticals shares, with 8.23% of its total shares outstanding invested in 17.22M BioCryst Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools